ChemotherapyFDA-approvedFirst-line
Alimta (Pemetrexed)
Generic name: pemetrexed
How it works
Interferes with the growth and spread of cancer cells by blocking the production of DNA and RNA.
Cancer types
Lung Cancer— All patients
Efficacy
In clinical trials, pemetrexed improved overall survival in patients with non-small cell lung cancer, with a median overall survival of approximately 10 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| New Treatment Combination Tested for Lung Cancer Patients with Brain Metastases | Lung Cancer | phase-1 | — | Source → |
| Testing Sacituzumab Tirumotecan in Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Methoxyamine with Cisplatin and Pemetrexed in Advanced Cancer Patients | Lung Cancer | phase-1 | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.